Semaglutide(link:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html) is a novel GLP-1 (human glucagon like peptide-1) analogue developed by Novo Nordisk. It has similarities with natural GLP-1, but has been structurally modified to increase its stability and biological activity. Semaglutide's CAS 910463-68-2, with molecular formula C24H30N6O7S, contains carbon (C), hydrogen (H), nitrogen (N), oxygen (O), and sulfur (S) elements. The molecular weight ranges from 1700 Daltons to 1800 Daltons. Due to its unique chemical structure, Semaglutide has good stability. Under normal storage conditions, it is not easily decomposed and has a longer duration of efficacy maintenance. Highly active GLP-1 receptor agonists can bind to and activate GLP-1 receptors, thereby exerting physiological effects such as regulating blood sugar and fat metabolism. Semaglutide is a novel GLP-1 (human glucagon like peptide-1) analogue developed by Novo Nordisk. Due to its unique chemical structure and biological activity, Semaglutide has broad application potential in medicine and drug development.
1. Treatment of diabetes: Semaglutide is a very effective GLP-1 receptor agonist, which can bind to GLP-1 receptor and activate them, thus stimulating insulin secretion and inhibiting glucagon secretion. Therefore, Semaglutide can be used to treat diabetes to control blood sugar level. In clinical trials, Semaglutide significantly reduced the blood sugar level of patients with diabetes, as well as weight and blood pressure.
The following are the main applications of Semaglutide in diabetes:
1.1 Control blood sugar levels: Semaglutide reduces blood sugar levels by stimulating insulin secretion and inhibiting glucagon secretion. In clinical trials, Semaglutide significantly reduced the blood sugar level of patients with diabetes, as well as weight and blood pressure. Therefore, Semaglutide can be used as an effective means to treat diabetes.
1.2 Improvement β Cell function: Semaglutide can improve β Cell function, promoting insulin secretion and inhibiting glucagon secretion. This will help diabetes patients better control their blood sugar levels and reduce the risk of complications.
1.3 Weight loss: Semaglutide can suppress appetite and promote fat breakdown, thereby reducing calorie intake and weight. In clinical trials, Semaglutide significantly reduced the weight of overweight and obese patients, which is very important for the treatment and management of diabetes patients.
1.4 Reducing cardiovascular risk: Semaglutide can reduce the blood lipid level and blood pressure of patients with diabetes, which helps reduce the risk of cardiovascular events. In clinical trials, Semaglutide can significantly reduce LDL-C (low density lipoprotein cholesterol) and triglyceride levels, while also increasing HDL-C (high-density lipoprotein cholesterol) levels.
1.5 Single drug therapy or combination therapy: Semaglutide can be used as a single drug therapy or in combination with other drugs, such as metformin, sulfonylurea, etc. This helps patients with different conditions to better control their blood sugar levels and reduce the risk of complications.
2. Weight loss medication: Semaglutide can also be used for weight loss. It can suppress appetite and promote fat breakdown, thereby reducing calorie intake and weight. In clinical trials, Semaglutide significantly reduced the weight of overweight and obese patients, while also improving metabolic indicators.
3. Neuroprotective agent: Semaglutide has neuroprotective effects and can protect nerve cells from damage or death. In animal models, Semaglutide can alleviate nerve cell damage and death, and improve neural function. Therefore, Semaglutide can be used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.
In the application of neuroprotective agents, Semaglutide exhibits neuroprotective effects due to its activation of GLP-1 receptors. The GLP-1 receptor is expressed in both the central and peripheral nervous systems, making Semaglutide a neuroprotective agent for the treatment of various neurodegenerative diseases.
3.1 Parkinson's disease: Parkinson's disease is a common neurodegenerative disease that mainly affects middle-aged and elderly people. In preclinical models, Semaglutide demonstrated therapeutic effects on Parkinson's disease by activating the GLP-1 receptor. It can reduce neuronal death, alleviate inflammatory reactions, and promote neuronal regeneration. These effects can improve the symptoms of Parkinson's disease patients and delay the progression of the disease.
3.2 Alzheimer's disease: Alzheimer's disease is a neurodegenerative disease characterized by decreased memory and cognitive function. Semaglutide can be reduced by β The deposition of amyloid protein and the improvement of neuronal function to treat Alzheimer's disease. In preclinical models, Semaglutide showed the ability to reduce β The ability to deposit amyloid proteins, alleviate inflammatory reactions, and promote neuronal functional recovery. These effects help improve the symptoms of Alzheimer's disease patients and delay the progression of the disease.
3.3 Atrophic lateral sclerosis (ALS): ALS is a rare neurodegenerative disease that mainly affects motor neurons. In the preclinical model, Semaglutide showed therapeutic effects on ALS. It can protect motor neurons from death and promote neuronal regeneration. These effects can improve the symptoms of ALS patients and delay the progression of the disease.
4. Antitumor drugs: Semaglutide can also be used for anti-tumor treatment. In animal models, Semaglutide can inhibit the growth and diffusion of tumor cells and enhance the anti-tumor activity of immune cells. Therefore, Semaglutide can be used to treat a variety of tumors, such as pancreatic cancer, colorectal cancer and non-small cell lung cancer.
5. For the treatment of other metabolic diseases:
In addition to diabetes and neuroprotective agents, Semaglutide can also be used to treat other metabolic diseases.
5.1 Obesity: Semaglutide can suppress appetite and promote fat breakdown, thereby reducing calorie intake and weight. In clinical trials, Semaglutide significantly reduced the weight of overweight and obese patients. In addition, Semaglutide can also improve metabolic indicators such as blood lipids and blood sugar levels, thereby reducing the risk of obesity related complications.
5.2 Hypertension: Semaglutide can lower blood pressure by improving insulin resistance and inflammatory response. In clinical trials, Semaglutide can reduce the blood pressure level of patients with diabetes, which helps reduce the risk of cardiovascular events.
5.3 Hypercholesterolemia: Semaglutide can reduce LDL-C (low density lipoprotein cholesterol) and triglyceride levels, while increasing HDL-C (high-density lipoprotein cholesterol) levels. This helps to improve blood lipid levels and reduce the risk of cardiovascular events.
5.4 Non alcoholic fatty liver disease (NAFLD): NAFLD is a common metabolic disease typically associated with obesity, hypertension, and dyslipidemia. Semaglutide can alleviate symptoms of NAFLD by improving insulin resistance and fat metabolism. In preclinical models, Semaglutide can reduce liver cell fat deposition and inflammatory response, thereby improving the condition of NAFLD.
5.5 Polycystic ovary syndrome (PCOS): PCOS is a metabolic disease that affects female fertility and is typically associated with insulin resistance and obesity. Semaglutide can alleviate symptoms of PCOS by improving insulin resistance and reducing appetite. In preclinical models, Semaglutide can improve insulin resistance and ovarian function, thereby contributing to the treatment of PCOS.
Other uses: In addition to the above, Semaglutide can also be used to treat other metabolic diseases, such as obesity, hypertension, high cholesterol, and dyslipidemia. In addition, Semaglutide can also be used to develop other drugs, such as combination therapy with other drugs or as a drug carrier.